MedTrace Logo

Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)

NCT00562406 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-07-22

No results posted yet for this study

Summary

The primary objective of this pilot study is to compare the functional and anatomic outcomes of chronic macular edema secondary to branch retinal vein occlusion (BRVO) treated with argon laser photocoagulation versus intravitreal ranibizumab (Lucentis®) injection versus a combination of both.

Conditions

  • Macular Edema

Interventions

DRUG

Ranibizumab

intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8

PROCEDURE

Laser photocoagulation

laser photocoagulation to the retina at the area of edema

Sponsors & Collaborators

  • Norvartis Pharma, Nuremberg, Germany

    collaborator UNKNOWN

  • Coordination center for clinical studies, Mainz, Germany

    collaborator UNKNOWN

  • Klinikum Ludwigshafen

    lead OTHER

Principal Investigators

  • Lars-Olof Hattenbach, MD, Privatdozent · Dept. of Ophthalmology, Ludwigshafen hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00562406 on ClinicalTrials.gov